arrow_back Trending Legislation
Share share

Stopping Drug Monopolies: Faster Access to Affordable Generic Medicines

New rules aim to speed up the market entry of cheaper generic and biosimilar drugs. The Federal Trade Commission (FTC) gains tools to penalize companies that intentionally delay this process by filing baseless petitions. This could lead to lower drug prices and more choices for patients.
Key points
The FTC can penalize companies filing baseless petitions to delay generic drug approval.
Financial penalties can be substantial, including revenue from drug sales or $50,000 per day of delay.
The goal is to increase competition in the pharmaceutical market and facilitate access to more affordable medicines.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Stop STALLING Act
Print number: S 1425
Sponsor: Sen. Klobuchar, Amy [D-MN]
Process start date: 2021-04-28
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Stopping Drug Monopolies: Faster Access to Affordable Generic Medicines

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 1425.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-04-28.

What are the main provisions?

Key points include:

  • The FTC can penalize companies filing baseless petitions to delay generic drug approval.
  • Financial penalties can be substantial, including revenue from drug sales or $50,000 per day of delay.
  • The goal is to increase competition in the pharmaceutical market and facilitate access to more affordable medicines.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Klobuchar, Amy [D-MN].

What is the latest detailed status?

The latest detailed status is: Placed on Senate Legislative Calendar under General Orders. Calendar No. 179.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

Analysis and Potential Impact of S 1425

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Courts and Law Economy